Last updated: February 14, 2026
What is Tadalafil and Its Market Position?
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor approved for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Marketed as Cialis by Eli Lilly and generics by multiple manufacturers, it is among the top-selling ED drugs globally.
How Large is the Current Tadalafil Market?
The global ED treatment market was valued at approximately $4.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6% through 2028. Tadalafil accounts for about 55% of the market share, making it the leading PDE5 inhibitor alongside sildenafil.
| Metric |
2022 Estimate |
Notes |
| Total ED market |
$4.3 billion |
Source: GlobalData |
| Tadalafil share of market |
55% |
Estimated from sales data |
| Tadalafil revenues |
~$2.37 billion |
Calculated from above |
| Growth rate (CAGR 2023–2028) |
6% |
Projected |
The growth is driven by increasing prevalence of ED and BPH, expanding aging populations, and rising acceptance of ED treatments. The market for PAH, a secondary indication, adds approximately $1.5 billion globally, with tadalafil securing a significant revenue share.
How Will Sales Evolve Over the Next Five Years?
Sales projections for tadalafil suggest the market will expand due to:
- Increased awareness and destigmatization of ED treatment.
- Broader insurance coverage in key markets.
- Launches of high-strength formulations and combination therapies.
By 2028, global sales of tadalafil may reach between $3 billion and $3.5 billion, assuming the 6% CAGR persists and market conditions remain favorable. Competitive pressures from sildenafil and vardenafil variants will limit full market penetration, but tadalafil’s longer half-life and dosing flexibility favor its growth.
What Key Factors Will Influence Market Growth?
- Regulatory Approvals: New indications or formulations in major markets (e.g., Asia, Europe) can unlock additional revenues.
- Patent Expirations: Expiry of Lilly’s patent in the U.S. in 2018 opened opportunities for generics, which now hold approximately 45% of sales.
- Pricing Strategies: Premium pricing in developed markets versus aggressive pricing strategies in emerging economies influence revenue.
- Competitive Landscape: Presence of generics, entry by new PDE5 inhibitors, and potential biosimilar developments shape sales trajectories.
- Research and Development: Pipeline drugs targeting ED and BPH could challenge tadalafil’s market share if approved successfully.
How Do Generics Impact the Market?
The generic entry in 2018 significantly reduced tadalafil’s price points. According to IQVIA, generic tadalafil accounts for roughly 45% of sales but at significantly lower prices—up to 80% discounts compared to brand-name Cialis. The resulting price competition has pressure on margins but expanded access, especially in emerging markets.
| Perspective |
Brand-Name Cialis |
Generics (Tadalafil) |
| Average price per pill |
$20–$25 |
$4–$6 |
| Market share (2022) |
55% |
45% |
What Are the Major Regulatory and Patent Trends?
- Lilly’s patent on Cialis expired in the US in 2018, allowing generics.
- Patent litigations in key jurisdictions (e.g., India, Europe) continue, affecting market entry and pricing.
- New formulations, such as once-weekly tablets, are under development to extend lifecycle.
What Are the Sales Outlooks for Related Indications?
- BPH: Tadalafil’s approved for BPH; sales are growing at a CAGR of 4%. It generated approximately $800 million globally in 2022.
- PAH: Contributes around $1.5 billion globally, with stable growth, but is less impacted by patent or generic competition.
How Do Competitive PDE5 Inhibitors Compare?
| Drug |
Market Share |
Formula Type |
Approved Uses |
Dosing Frequency |
| Tadalafil |
55% |
PDE5 inhibitor |
ED, BPH, PAH |
Once daily/weekly |
| Sildenafil |
30% |
PDE5 inhibitor |
ED, PAH |
As needed |
| Vardenafil |
15% |
PDE5 inhibitor |
ED |
As needed |
Tadalafil’s longer half-life (17.5 hours) enhances selectivity for daily and long-term use. Sildenafil’s shorter half-life (4 hours) limits its convenience but maintains a strong cost advantage.
Key Growth Drivers and Risks
- Drivers: Aging populations, increased awareness, new formulations.
- Risks: Patent expirations, pricing pressures, regulatory delays, off-label use restrictions.
Final Sales Projections Summary
| Year |
Estimated Global Sales of Tadalafil |
Notes |
| 2023 |
~$2.5 billion |
Recovery from patent expirations, steady growth |
| 2024 |
~$2.66 billion |
Market expansion, new indications |
| 2025 |
~$2.83 billion |
Increased generic penetration, pipeline progress |
| 2026 |
~$3.0 billion |
Potential new formulations, market stabilization |
| 2028 |
$3.3–3.5 billion |
Continued growth, potential new indications approved |
Key Takeaways
- Tadalafil remains a leading drug in ED and BPH markets, with global sales approaching $2.5 billion in 2023.
- Market growth is sustained by aging demographics, patent cliffs, and expanding indications.
- Generics have halved prices but maintain a substantial market share, constraining margins.
- Future growth hinges on R&D efforts, regulatory decisions, and market expansion in emerging economies.
FAQs
1. What factors limit tadalafil’s market growth?
Patent expirations, pricing pressures from generics, and regulatory hurdles on new formulations can slow growth.
2. How significant are tadalafil’s other indications in sales?
BPH contributes approximately $800 million annually, while PAH accounts for about $1.5 billion. These secondary indications provide steady revenue streams.
3. How do emerging markets influence sales projections?
Emerging markets are increasingly adopting ED treatments. Lower prices and expanding healthcare access support growth, though market penetration lags behind developed nations.
4. What upcoming regulatory changes could impact tadalafil sales?
Acceptance of new formulations, such as once-weekly dosing, and approvals for additional indications can expand market size.
5. How do the competitive PDE5 inhibitors compare in sales and features?
Tadalafil’s longer half-life allows for daily and weekly dosing, unlike sildenafil and vardenafil, which are mainly used as needed. Pricing discounts and patent expirations affect their respective market shares.
References
- GlobalData. "Erectile Dysfunction Market Analysis." 2022.
- IQVIA. "Pharmaceutical Market Data." 2022.
- Eli Lilly. "Cialis Product Information." 2023.
- MarketWatch. "Global PDE5 Inhibitors Market Size." 2022.
- EvaluatePharma. "Biopharma Market Trends." 2022.
